78351-75-4
78351-75-4 结构式
基本信息
1-(3-氯苯胺基)-4-苯基酞嗪
N-(3-氯苯基)-4-苯基酞嗪-1-胺
MY 5445
MY5445
1-(3-CHLOROANILINO)-4-PHENYLPHTHALAZINE
1-(3-Chloroanilino)-4-phenylphthalazine >
1-(3-CHLOROPHENYLAMINO)-4-PHENYLPHTHALAZINE
N-(3-chlorophenyl)-4-phenylphthalazin-1-amine
N-(3-Chlorophenyl)-4-phenyl-1-phthalazinamine
物理化学性质
常见问题列表
|
PDE5 1.3 μM (Ki) |
PDE5 6.7 μM (IC 50 ) |
PDE4 37 μM (IC 50 ) |
MY-5445 inhibits human platelet aggregation by increasing cyclic GMP content and that it provides a useful probe for elucidating the role of cyclic GMP in platelet aggregation .
MY-5445 selectively reverses ABCG2-mediated multidrug resistance in ABCG2-overexpressing cells.
MY-5445 reverses ABCG2-mediated multidrug resistance (MDR) by potentiating the cytotoxicity of an ABCG2 substrate drug in ABCG2-overexpressing multidrug-resistant cancer cells, possibly by modulating the function and/or the protein expression of ABCG2.
MY-5445 (3 μM; 48 hours) substantially increases the topotecan-induced apoptosis in S1-M1-80 cell.
Apoptosis Analysis
| Cell Line: | Human S1 colon cancer cells, S1-M1-80 cancer cells |
| Concentration: | 3 μM |
| Incubation Time: | 48 hours |
| Result: | Enhanced drug-induced apoptosis in ABCG2-overexpressing cancer cells. |
MY-5445 (0.5-3 mg/kg; i.p.; twice a day; for 15 days) produces a significant relief of mechanical hypersensitivity.
| Animal Model: | C57BL/6J male mice |
| Dosage: | 0.5 mg/kg, 3 mg/kg |
| Administration: | Intraperitoneal injection, twice a day, for 15 days |
| Result: | Alleviated the cuff-induced allodynia. |